Maraviroc is the first US Food and Drug Administration-approved drug from a new class of
antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a …

Sexual transmission of human immunodeficiency virus type 1 (HIV-1) across mucosal
barriers is responsible for the vast majority of new infections. This relatively inefficient …

Abstract Human ANP32A and ANP32B are essential but redundant host factors for influenza
virus genome replication. While most influenza viruses cannot replicate in edited human …

The identification of chemokines in blood platelets has strengthened our view of these cells
as participants in immune host defense. Platelet chemokines representing prestored and …

RECEPTORS Chemokines are small 70 amino acid long soluble proteins that chemoattract
a variety of mononuclear cell types to sites of inflammation or secondary lymphoid organs by …

Since the discovery of CCR5 as a coreceptor for HIV entry, there has been interest in
blockade of the receptor for treatment and prevention of HIV infection. Although several …

The identification of phenotypically distinct HIV-1 variants with different prevalence during
the progression of the disease has been one of the earliest discoveries in HIV-1 biology, but …

ABSTRACT CCR5 antagonists inhibit HIV entry by binding to a coreceptor and inducing
changes in the extracellular loops (ECLs) of CCR5. In this study, we analyzed viruses from …

Abstract Maraviroc (Celsentri®; Selzentry®) is a CCR5 coreceptor antagonist used in the
treatment of CCR5-tropic HIV-1 infection. Administered orally twice daily, maraviroc, in …

Mutations in GJB2 (gap junction protein, beta-2) are the major cause of autosomal recessive
non-syndromic hearing loss. A few allele variants of this gene also cause autosomal …